Episode summary
Can The LinkedIn For Doctors Be a 10-Bagger?
The Intrinsic Value Podcast
· · 1 hr 10 min · Hosts: Shawn O'Malley, Daniel Mahncke
Summary
Doximity is presented as a niche healthcare platform that combines professional networking, workflow tools, and targeted advertising for physicians. The hosts argue that its real advantage is not “LinkedIn for doctors” branding, but the combination of verified physician identities, rich specialty data, and a highly concentrated audience that pharma brands can reach with unusually precise targeting. The company’s ad products are sold as subscriptions with guaranteed delivery, which the hosts say fits a small, sophisticated buyer base better than an auction model.
A major part of the pitch is that Doximity sits inside doctors’ daily workflow through telehealth, faxing, e-signatures, dialing, and AI writing tools like Docs GPT. The hosts say these tools are HIPAA-compliant, reduce administrative burden, and make the platform sticky, which in turn creates more advertising inventory and more monetization opportunity. They also note the Pathways acquisition and the push toward AI medical reference tools.
The bear case centers on trust and concentration. The hosts flag weak disclosure on active usage, a securities lawsuit over engagement claims, competition from Epic/MyChart and open evidence, dependence on pharma spending, and a compensation structure that they view as poorly aligned with shareholders. Despite strong reported economics, they are uneasy about how much of the business is real engagement versus registered-but-inactive accounts.
Key takeaways
- The hosts say Doximity’s moat is verified physician identity plus specialty-level targeting, not just audience size.
- They argue subscription-based ad sales make sense because more than 80% of revenue comes from about 100 clients.
- Docs GPT and related workflow tools could expand engagement, but the hosts see AI as optionality rather than the core thesis.
- The biggest risk is credibility: the hosts point to a lack of active-user disclosure and a federal securities lawsuit over engagement claims.
- Management ownership is high, but the hosts still rate the compensation structure poorly because it leans on revenue and adjusted EBITDA targets.
- At roughly 30x forward earnings, the hosts think valuation is reasonable only if reported usage and monetization are as strong as management implies.
Notable quotes
“80% of doctors in the US all in one platform. Some call it the LinkedIn for doctors, but Doximity has much more to offer than just that”
“for context, targeted advertising draws 85% of the company's revenues while about 15% of revenues come from these enterprise level subscriptions”
“Since April 2024, the company and several of its officers have been named as defendants in a securities class action lawsuit centered around questions about user count and engagement rates”
How the episode opens
(00:00) 80% of doctors in the US all in one platform. Some call it the LinkedIn for doctors, but Doximity has much more to offer than just that. With Doc GBT, the company is materially cutting down on the admin work doctors have to do, which can count for as much as half their working days.
(00:19) Docimity is the networking and productivity solution for physicians. And despite all that fertile advertising ground for pharmaceutical businesses wanting to reach prescribing physicians, this is still a sub10 billion market cap business. Somehow we made it through our first year of covering companies on this show every single week without looking at any businesses that are solely dedicated to the healthcare world.
(00:51) That's probably a learned response from having the healthare system in the US at least make my head spin as an outside observer and honestly it would be the same in Germany. So rather than looking at a developer of pharmaceuticals or provider of healthcare insurance which we find to be just very difficult areas to understand and invest in the pitch for today is really a tech platform company that caters to healthcare professionals. That company is Doximity.
(01:16) And in reality, it's more like a scalable software business with sticky network effects and a suit of productivity products that are revamping how efficiently medical professionals can do their work because, well, let's be honest, healthcare is one of the last bastions of bureaucracy and paperwork that hasn't entirely been digitalized yet, especially on the back end. (01:36) Yes, maybe you have an app for your appointments and to message your doctor, but you would probably be surprised to learn just how inefficient the communication systems behind the scenes can actually be. Much of the medical world still runs on faxes, which surprised me, at least for the US.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- intrinsic value modeling
- doximity subscription advertising
- healthcare admin burden
- hipaa compliant ai productivity tools
- competitive moats in healthcare tech
Companies and tickers mentioned
- DOCS
- Doximity
Watch the episode
Watch “Can The LinkedIn For Doctors Be a 10-Bagger?” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from The Intrinsic Value Podcast
-
Canadian Pacific Kansas City Limited (CP.TO): Irreplaceable Moat, Unproven Compounding -
Reddit (RDDT): Record Cash Flow, Collapsing Share Price -
McDonald's ($MCD): Generational Compounder in Historical Drawdown -
Mercado Libre ($MELI): We Doubled Down on Meli! -
Airbnb (ABNB) The Business Outgrew Its Peak, the Stock Hasn't -
GE Aerospace: The Ultimate Compounder?
The Intrinsic Value Podcast, this episode and its artwork belong to The Investor's Podcast Network. Octagon is not affiliated with the show; this page is an independent summary.
